A Year in Review
Letter from Chief Executive Officer

Dear Friends,

On behalf of everyone engaged with the mission of the Cutaneous Lymphoma Foundation, we thank you for your generous support. Whether it is through a financial donation or gifts of time and talent, each and every person has a profound impact on the lives of those around the world suffering with cutaneous lymphoma.

The past year has been an active one for the CLF. We are more committed than ever to serving the needs of cutaneous lymphoma patients by promoting awareness and education, advancing patient care, and facilitating research. We continued our long-standing initiative of hosting live programs delivered around the country, culminating with the 3rd Annual 2-Day Education Conference in San Diego. Close to 100 people gathered together to hear from clinical experts about the disease basics with many opportunities for everyone to make new connections with others who share a similar journey. One of the additional program highlights was attending the first-ever International Dermatology Patient Organization Conference held in Vancouver, Canada in collaboration with the World Congress of Dermatology. This conference brought together patient leaders from around the globe to share ideas, insights and hear from advocacy experts about new ways to deliver much needed support to people living with skin diseases. Out of this meeting, a new worldwide organization was established called the International Alliance of Dermatology Patient Organizations that will serve as an umbrella group whose mission is to raise awareness of the challenges of people living with skin disease and advocate at the global health level on their behalf.

An exciting second year of our CLARIONS Research Award program culminated in renewal of the first two awards and adding two unique new awards. Tae Jin Kim, PhD from Stanford University School of Medicine, project is investigating Optical imaging of electron radiotherapy to promote uniform total skin irradiation, and Sergei Koralov, PhD, from New York University School of Medicine, project is deciphering the role of skin microbiota in CTCL pathogenesis. We are thrilled to have the financial capacity to support these researchers and their important work.

This year also saw some changes in two long-term members of our Board of Directors. After 16 years of dedicated service, Dr. Stuart Lessin has stepped down from active Board service. As many of you know, Dr. Lessin was integral in getting the CLF off the ground and will continue to serve as Chair of the Scientific Review Committee. Board President, Chris Shipp has also decided to step down from his long-term Board service over the last 10+ years. We are grateful to Dr. Lessin and Chris for their many years of committed service and wish them well.

Board Member, Joe Eischens, Esquire, stepped forward to take on the leadership role of Board President. As a patient himself, Joe, like many of us, is in current treatment for his cutaneous lymphoma while living an active professional life as an attorney serving people who have suffered from discrimination along with enjoying time with his wife and two children. He brings to the Board a passion for helping us create a sustainable infrastructure so that everyone who is diagnosed with this rare disease, wherever they live, can find support here at the CLF. We are thrilled to have Joe step into this critical volunteer position.

Susan Thornton, CEO
I am honored to accept this new position as President of the Board. As I begin my journey in this leadership role, I am inspired by how far the organization has come in the last 15 years with a small staff and dedicated members of the Board. I am committed to working collaboratively with my fellow Board members and the CLF staff to continue the innovation and initiatives to bring education and support to people around the world as well as grow our research program to allow us to support the critical work of the dedicated investigators trying to find answers to the many questions about this disease.

As we look to next year, we will continue to serve those who need us most by providing the knowledge and resources related to treatment, quality of life and ensure that patients are armed with as much information as possible to make important and informed treatment decisions along with their medical team. New and innovative initiatives are on the horizon that will enable more people to connect to the CLF in a meaningful way along with continuing the CLARIONS research grant program to support important work necessary to unlock the mysteries around cutaneous lymphoma that can help find new treatments and better ways for earlier diagnosis.

Each day, as we fight against this rare disease and all of its challenges, the staff and Board keep in mind that there is an individual behind the diagnosis who looks to us to provide support, sound information and hope. With each step forward, and each individual we touch, we continue to dedicate our efforts to serving all people impacted by cutaneous lymphoma.

Thank you for being an integral part of our community. Together we can bridge the knowledge gap and strive toward a time when a diagnosis of cutaneous lymphoma is nothing more than a brief detour in a long and rich life.

Joe Eischens, Esq.
President, CLF Board of Directors

Contents:
Board of Directors & Staff ...........................................4
A Year in Review ..........................................................6
Financials .................................................................8
Donors .......................................................................10
All Donors .................................................................11
Looking Forward .........................................................15
The mission of the Cutaneous Lymphoma Foundation is to support every person with cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. We exist to make sure that each person with cutaneous lymphoma gets the best care possible.
What is Cutaneous Lymphoma?

Cutaneous lymphomas are cancers of lymphocytes (white blood cells) that primarily involve the skin. Classification is based upon lymphocyte type: B-lymphocytes (B-cell) or T-lymphocytes (T-cell).

Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma that typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration, and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood, and internal organs.

Cutaneous lymphomas affect thousands of individuals worldwide. It is estimated that over 30,000 people in the United States alone have been diagnosed with some form of lymphoma. The incidence of cutaneous T-cell lymphoma in the United States is increasing with approximately 3,000 new cases being diagnosed annually. Due to the difficulty of diagnosing the disease in its early stages and the current lack of an accurate reporting system, prevalence of cutaneous lymphoma is thought to be much higher.
A Year in Review

Patient Support Services
• Connected with 1000+ individual patients and caregivers in person and via telephone or email from around the world.
• Began Patient Networking Groups in New York City, New York

Patient Education
• Held 6 full-day Patient Educational Forums
• Introduced our Answers from the Experts...LIVE! programs and held 5 evening programs
• Held third 2-Day Patient Conference in San Diego, CA
• Served 200+ patients and caregivers through these events in 12 cities throughout the United States.
• Added videos on CBCL and ALCL to Online Learning Center

Medical Meetings
• American Society of Hematology (ASH), San Francisco, CA
• American Academy of Dermatology (AAD), San Francisco, CA
• American Society of Clinical Oncologists (ASCO), Chicago, IL
• European Organization for Research and Treatment of Cancer (EORTC) and Cutaneous Lymphoma Task Force (CLTF), Paris, France
• Society of Investigative Dermatology (SID), Atlanta, GA
• Dermatology Nurses Association (DNA), Las Vegas, NV
• International Society for Cutaneous Lymphoma (ISCL)
• T-Cell Symposium, San Francisco, CA
• United States Cutaneous Lymphoma Consortium (USCLC) Annual Workshop, San Francisco, CA
• World Congress of Dermatology, Vancouver, Canada

Research
• Awarded CLARIONS Research Awards to Tae Jin Kim, PhD of Stanford University School of Medicine and Sergei Koralov, PhD of the New York University School of Medicine. CLARIONS Research Awards were renewed for a continuing year to Leandro Cerchietti, MD of Weill Cornell Medical College and Rachael Clark, MD, PhD of Harvard Medical School.
• Young Investigator Awards were presented to Tomomitsu Miyagaki, MD, PhD, The University of Tokyo Graduate School of Medicine, Japan (SID); Filiberto Cendeno Laurent, MD, PhD, University of Pennsylvania (ASH)
Publications
• Published 2015 Research Report - CLF’s first report for the CLARIONS Research Grant
• Published three Forum newsletters and 12 e-Newsletters

Advocacy
CLF Board & staff attended a variety of advocacy meetings and policy programs in Washington, DC held throughout the year, including two legislative lobby days on Capitol Hill:
• One Voice Against Cancer - CLF was represented by Joe Eischens, CLF Board President
• American Academy of Dermatology Captiol Hill Day - CLF was represented by staff member, Deb Van Zegeren
• CLF became an active member of the Partnership to Improve Patient Care (PIPC).
• CLF joined the Lymphoma Education and Advocacy Partners (LEAP), the advocacy arm of the Lymphoma Research Foundation

Collaborative Partners included:
A special “Thank You” to the below organizations for their support of our efforts and the opportunity to work together on behalf of those we serve:
• Canadian Patient Skin Alliance
• CancerCare - joined with the CLF to provide meeting space and support for our New York Networking Group
• Coalition of Skin Diseases
• International Alliance of Dermatology Patient Organizations - CLF is a founding member this organization
• Lymphoma Coalition
• Lymphoma Research Foundation
• Patient Advocate Foundation
• Regulatory Education and Action for Patients
• T-Cell Leukemia Lymphoma Foundation

What I found most helpful... was the realization I’m not the only person with CTCL.

Patient Educational Forum Attendee
# Statement of Financial Position • Year Ending June 30, 2015

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>875,846</td>
<td>1,050,723</td>
</tr>
<tr>
<td>Promises to give</td>
<td>43,000</td>
<td>7,775</td>
</tr>
<tr>
<td>Inventory</td>
<td>2,155</td>
<td>2,919</td>
</tr>
<tr>
<td>Total current assets</td>
<td>921,001</td>
<td>1,061,417</td>
</tr>
<tr>
<td><strong>FIXED ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>708</td>
<td>1,546</td>
</tr>
<tr>
<td>Total fixed assets</td>
<td>708</td>
<td>1,546</td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid rent</td>
<td>1,019</td>
<td>1,019</td>
</tr>
<tr>
<td>Security deposit</td>
<td>1,333</td>
<td>1,333</td>
</tr>
<tr>
<td>Total other assets</td>
<td>2,352</td>
<td>2,352</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$924,061</td>
<td>$1,065,315</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>18,579</td>
<td>20,214</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>90,832</td>
<td>83,093</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>109,411</td>
<td>103,307</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>159,448</td>
<td>323,988</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>655,202</td>
<td>638,020</td>
</tr>
<tr>
<td>Total unrestricted net assets</td>
<td>814,650</td>
<td>962,008</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td>$924,061</td>
<td>$1,065,315</td>
</tr>
</tbody>
</table>

*Financial figures taken from independently audited financial statements.
Statement of Activities • Year Ended June 30, 2015

<table>
<thead>
<tr>
<th>SUPPORT AND REVENUE:</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and grants</td>
<td>162,681</td>
<td>575,515</td>
<td>738,196</td>
</tr>
<tr>
<td>Merchandise sales, net of cost of goods sold of $784 in 2015 and $482 in 2014</td>
<td>(673)</td>
<td>0</td>
<td>(673)</td>
</tr>
<tr>
<td>Special events</td>
<td>600</td>
<td>0</td>
<td>600</td>
</tr>
<tr>
<td>Investment income</td>
<td>548</td>
<td>0</td>
<td>548</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORT AND REVENUE</strong></td>
<td><strong>163,156</strong></td>
<td><strong>575,515</strong></td>
<td><strong>738,671</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS RELEASED FROM TEMPORARY RESTRICTIONS</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>558,333</td>
<td>(558,333)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>721,489</strong></td>
<td><strong>17,182</strong></td>
<td><strong>738,671</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FUNCTIONAL EXPENSES:</th>
<th>Program</th>
<th>Management and general</th>
<th>Fundraising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>742,371</td>
<td>0</td>
<td>742,371</td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>71,933</td>
<td>0</td>
<td>71,933</td>
<td></td>
</tr>
<tr>
<td>Fundraising</td>
<td>71,725</td>
<td>0</td>
<td>71,725</td>
<td></td>
</tr>
<tr>
<td><strong>Total functional expenses</strong></td>
<td><strong>886,029</strong></td>
<td><strong>17,182</strong></td>
<td><strong>886,029</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHANGE IN NET ASSETS</th>
<th>Program</th>
<th>General Administrative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>(164,540)</td>
<td>17,182</td>
<td><strong>(147,358)</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS - Beginning of year</th>
<th>Program</th>
<th>General Administrative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>323,988</td>
<td>638,020</td>
<td><strong>962,008</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS - End of year</th>
<th>Program</th>
<th>General Administrative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$159,448</td>
<td>$655,202</td>
<td><strong>$814,650</strong></td>
<td></td>
</tr>
</tbody>
</table>

How Your Dollar Was Spent

<table>
<thead>
<tr>
<th>Programs</th>
<th>General Administrative</th>
</tr>
</thead>
<tbody>
<tr>
<td>72%</td>
<td>8%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research Funding</th>
<th>Fundraising</th>
</tr>
</thead>
<tbody>
<tr>
<td>12%</td>
<td>8%</td>
</tr>
</tbody>
</table>
Donors

The Cutaneous Lymphoma Foundation is deeply grateful to all of the donors who supported our mission through financial contributions during our 2014-2015 fiscal year (July 1, 2014 – June 30, 2015). Your gifts have enabled us to make sure each person with cutaneous lymphoma receives the best care possible and that the Foundation can continue to expand our programs and services to support those who need us most. Thank you for your support.

Visionary of Care Society
$10,000+ Annual Fund Campaign Giving

- Actelion Pharmaceuticals US, Inc.
- Adaptive Biotechnologies
- Avella Specialty Pharmacy
- Celgene Corporation
- Flince Research & Design
- Kyowa Hakko Kirin Pharma, Inc.
- Patients Like Me, Inc.
- Seattle Genetics
- Spectrum Pharmaceuticals
- TetraLogic Pharmaceuticals
- Therakos, Inc.
- Valeant Pharmaceuticals International, Inc.

Partner in Care Society
$5,000 - $9,999 Annual Fund Campaign Giving

- The Steve Euller and Nancy Roehr Family Charitable Fund

Friend in Care Society
$1,000 - $4,999 Annual Fund Campaign Giving

- Randolph Angermann
- Mary Argus
- Aschkenasy Family Fund
- Bakewell Foundation
- Gail and George Baril
- BQ6 Media Group, LLC
- Kent and Kay Colberg
- Amy B. Crowe
- Fidelity Charitable
- First Giving
- Steven Director
- Suzanne Gylfe
- Marilyn J. Harran
- Stuart R. Lessin
- The Chris & Melody Malachowsky Family Foundation
- Arthur and Laurie Malman
- Kelly Oddie
- Theresa Pacheco, MD
- Thomas Pledger
- Carlos S. Rodriguez
- Mark Rusley
- Patrick Ryan
- Linda Shaffer
- Anthony Sogliuzzo
- Patricia Sullivan
- Ron Swift
- United Way of King County
- United Way of Kansas City
- Danna Wessels & Nancy Noble
The following list includes all individual, corporate and foundation donors who contributed to our Annual Fund Campaign or supported other programs and services.

Larry Abe  
Jose Abreu  
Actelion Pharmaceuticals US, Inc.  
Adaptive Biotechnologies  
David Adelman  
Nida Ahmad  
Beverly Albert  
Frank & Emille Allen  
Andrea Allen  
Marla Almeida  
Fadwa Al-Taher  
Mr. & Mrs. Anthony Alterio  
Tricia Alvey  
AmazonSmile Foundation  
Ernestine Anania  
Tom Andrews  
Randolph Angermann  
Patricia Angley  
Ari Anolic  
Eddy Antunes  
Keith Anzel  
Lynne Arany  
Frank J. Arena  
Mary Argus  
Howard Aronson  
Linda Arthur  
Aschkenasy Family Fund  
Helen Ashton  
Ann Atkinson & Terrence Atkinson  
Avella Specialty Pharmacy  
MaryAnn & Reg Awtrey  
Judith Axelrod  
August Baetsle  
Axel Baeumler  
Sofia Bain  
Debra Baird  
Mark Baker  
Sally Baker  
Bakewell Foundation  
Blake Ballard  
William & Evelyn Barcomb  
Gail Baril  
Nicole Baril  
Betty Barnett  
Daniel Barolsky  
Mara Barry  
Elizabeth Bassan  
Herman Baur  
Margaret Baum  
Norbert Beauchemin  
Judy Beck  
Mary Ellen Behm  
Carlene Belanger  
The Benevity Community Impact Fund  
Dorothy Berchtold  
Vera Berlin Fund  
Bonnie Berteileen  
Dotti Berry  
Jessica Birch  
Frank Birney  
Stephanie Blackmore  
David & Barbara Blandino  
Dorothy Bleiler  
Michael Block  
Eric Block  
David M. Bloom  
Ida Bohmstein  
Ron Bower  
BQ6 Media Group, LLC  
Kristina Bradley  
Richard B. Bradlow  
Michael Bragg  
Phil & Alison Braverman  
Renate Bremenke  
Linda Brewer  
The Brooks Group & Associates, Inc.  
Bruce Minkoff  
Ivan & Ana Budisin  
Judith Burgste  
Betty Burns  
Catherine Burris  
Carolyn Burrous  
Sally Busch  
Valerie Butera  
Bill & Joan Button  
Ellen Cameron  
James & Margery Carenzo  
Joe Carey  
Warren Casner  
Celgene Corporation  
Jean Cernak  
Elizabeth Cerri  
Pi Ling Chang  
Marilyn Charap  
Charles A. and Alice Jean Boyer Matuszak Family Fund  
Sandi Chatz  
Pamela Chumley  
Carole Chung  
Philip Church  
Clorox Company Foundation  
Noal Cohen  
Wallace M. Cohen  
Kent & Kay Colberg  
Merle & Arnold Cole  
Fred & Gail Colvin  
Diane Coyer  
Community Health Charities of CA  
William & Janis Conner  
Warren A. Cooper, Warren L. Cooper & Peggy Randles  
Julie Costa  
Rhea Cox  
Amy B. Crowe  
Phyllis Crump  
Shannon M. Curren  
Marion Dagenais  
Anita Dalia  
Regina & Danny D’Angelo  
William Davidson  
Lidia Davidson  
Claudia Day  
Thomas Day  
Ronald Decker  
Joseph DeFina  
Mary L. Del Vecchio  
Dermasurgery Center  
Susan Devine  
Neil and Linda Dicker  
Jackie Dildy  
Steven Director  
Richard Dodds  
Donald Dorer  
Cheryl Downen  
Martha Drilling  
Dov Drizin  
Mark Drusin
Theresa Matsey
Katherine Matthews
Helen & Jeff Mattox
Leslie Maurer
Kenneth Mawson
Helen R. Mayville
Molly McCarthy
Annette McDonald
Richard McInnes
Kim McKenzie-Camp
Natalie McLain
Kati McNeal
Jamie Meachan
Kathleen Meagher
Jan Susan Medved
Kathleen Meier & David Perry
Jane Meiners
Merck Foundation
Nancy Meredith
Gayle Metcalf
Bill & Donna Metheny
Donna Milko
Lloyd Miller
Mark Miller
Donald G. Miller
Daniel Miller
Jennifer Mills
Marc Miner
Maryida Mirabella
Ronald & Carolyn Miscko
Margaret Montgomery
Hope Morgan
Morgan Stanley
Paul Morrison
William D. Mosher
Ann Moskowitz
Jane A. Mullen
Vicki and Icalo Musa
Helen Muscat
Ronald Nappi
Nationwide United Way Campaign
Linda Nessly Allison
Network for Good
Jim & Judie Neville
Alan Nicholas
Claudia Nogueira
Caitlin Norris
Sharon & Neil Novick
Kelly Odle
Sherri Oliver

Tim Olsen
Elise Olsen
Tuba Ocnu
Sylvia Osborne
Barbara Ostberg
Karen Paikin
Jesse Paikin
Bill Panella
James & Sharon Parkman
Patients Like Me, Inc.
James Pattie
Michele Pawluk
Penney Peerce
Andrew Pelletier
Judy Peloquin
Cheryl Perkins
Marilyn Perlotto
Wanda Peters
Douglas Peters
James M. Pherson
Mark Pipal
John Plank
Thomas Pledger
Laura Pratt & John Grew
Holly Pribe
Robert Pursel
Myrna W. Pyke
Robert M. Pyle, Jr.
Tova Rafael
Raphaelson Levine Law Firm
Daniel Ray
Beff Ray
Patricia Ray
Dan Reed
Elaine Reimbold Pitkin
Carolyn Renz
Allan R. Rexinger, Esq.
Mick & Patty Reynolds
Mary Reynolds
Cheryl Romine
Deborah Richards
Donna Ringelstein
Ronald & Bridget Ritter
Robert Roberts
Ruth Roberts
Rick & Susan Robillard
Joan & Rick Rocamora
Carlos S. Rodriguez
Johnnie Rogers
Gary Rose

Rosenson Foundation
John Roush
Craig Roy
Eugene & Janet Roy
Louis Roy
Kaye Ruskey
Mark Rusley
Bria Colyer Russo
Frederick Ruvkun
Patrick Ryan
Sally Dietz
Robert & Diane Saltzman
Elizabeth Sauer
Lorraine Sauter
Lilianna Scali
Gerald & Sharon Scheffler
Gloria & Ernie Schell
Sandra Schleede
Amy Schlesinger
Caryn Schlesinger
David Schmidt
Katherine Schneider
Zac Schroeder
Teresa Schruben
Ellen Schwartz
Robert Schwartz
Barbara Schwartz
Herman Schwartzman
Laurie Scott
Laurie S. Scott
Britt Scott
Mary Scott
Seattle Genetics
Linda Seibert
Select Resources
Linda Shaffer
Ann Shaw
Michael Shechtman
Karen Sherman
Jianfeng Shi
Michi Shishoyama, MD
Mary K. Shoemaker
Phyllis Shurgin
Johnny Signater
Larry P. Simmons
Yvette Simmons
Mary Singleton
Ed & Mary Skoneski
Susan Slaviero

Adam Smith
Robert Smith
Judy & Al Smith
Stephanie Smith
Veda Smith
Karen Snow
Bob Snyder
Stu Sodell
Anthony Sogliuzzo
Libby Sorkin Routman
Cynthia & Ralph Sowden
Spectrum Pharmaceuticals
Michael Spivak
John Sredniawski
Miriam Stallings
Janice & Dan Staniszewski
Linda Stapley
Mr & Mrs. David Staplin
Paula Star
Robert Steele
C. Jeffrey Stein
Staci Stephens
Marsha Stevens, RN, BSN
Jeffrey and Mary Stevens
Susan C. Stevens
Sherrie Stille
Ann Stinson
John & Nancy Stires
Beverly Stauss
Kathy Stroube
Emily Strulson
Mark Swerdlik
Ron Swift
Accuracy Statement

The report recognizes contributions received by the Cutaneous Lymphoma Foundation July 1, 2014 through June 30, 2015. Please accept our apologies if we have made any errors or omissions with your name or gift. If your listing requires correction, please contact us at info@clfoundation.org or 248.644.9014.

Cutaneous Lymphoma Foundation’s 2014-2015 Corporate Partners

[Brands and logos]
Looking Forward

Looking ahead to the next fiscal year and beyond, we are focusing on the following programs and initiatives:

• Adding new ways for people to participate and view our live events through technology using live streaming services;

• Add translation tool to website to increase accessibility to non-English speaking users;

• Increasing number of Annual 2-Day Patient Education Conference to two per year;

• Funding of new CLARIONS Research Awards and the renewal of the second year awards;

• Celebrating our researchers and clinical supporters at our annual reception at the American Society of Hematology;

• Growth and enhancement of the CLF staff and Board of Directors;

• Increase ways for individuals to become part of the growing CLF community through direct support of CLF and its mission.

I discovered the Foundation quickly after (my husband’s) diagnosis. It is now our only resource because it has met all our needs. Everyone with whom we’ve had contact has been informative, supportive and sincerely empathetic.

2-Day Patient Conference Attendee